Showing results (311-320 of 352) with videos related to
Sort By:
Pageof 36
Arthritis Research & Therapy|February 12, 2024
Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trialsAtul Deodhar, Andrew Blauvelt, Mark Lebwohl, et al.The Journal of Allergy and Clinical Immunology|July 15, 2023
Oral difelikefalin reduces moderate to severe pruritus and expression of pruritic and inflammatory biomarkers in subjects with atopic dermatitisEmma Guttman-Yassky, Paola Facheris, Joel Correa Da Rosa, et al.The Journal of Allergy and Clinical Immunology|December 22, 2018
Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseasesTali Czarnowicki, Helen He, Alexandra Leonard, et al.Journal of the American Academy of Dermatology|October 9, 2009
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapyAlan Menter, Neil J Korman, Craig A Elmets, et al.Journal of the American Academy of Dermatology|February 17, 2009
Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapiesAlan Menter, Neil J Korman, Craig A Elmets, et al.Journal of the American Academy of Dermatology|October 16, 2013
Research gaps in psoriasis: opportunities for future studiesCaitriona Ryan, Neil J Korman, Joel M Gelfand, et al.JAMA Dermatology|July 9, 2025
Ixekizumab and Malignant Neoplasms: A Pooled Analysis of Data From 25 Randomized Clinical TrialsJoseph F Merola, Kim A Papp, Atul Deodhar, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|March 6, 2025
Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trialsApril W Armstrong, Mark Lebwohl, Richard B Warren, et al.Journal of the American Academy of Dermatology|June 5, 2009
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agentsAlan Menter, Neil J Korman, Craig A Elmets, et al.Journal of the American Academy of Dermatology|April 26, 2025
Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trialAndrew Blauvelt, Richard G Langley, Mark Lebwohl, et al.Pageof 36